Back

In vivo models for oncology

With strong expertise in oncology models, advanced surgical techniques, and biomarker-driven endpoints, Biotrial delivers customized nonclinical strategies tailored to the specific biology of your compound and therapeutic target.

By combining predictive cellular models with sophisticated in vivo tumor systems and advanced analytical capabilities, our nonclinical teams help sponsors generate the mechanistic and efficacy data required to confidently progress toward clinical development.

Customized immuno-oncology and translational animal models

Our teams have strong expertise in tumor implantation techniques, immuno-oncology models (syngeneic and humanized models), and longitudinal monitoring technologies, allowing precise evaluation of therapeutic responses.

Biotrial conducts tailored in vivo oncology studies designed to generate robust efficacy data and translational insights in physiologically relevant tumor models.

Each study is designed collaboratively with sponsors to ensure that model selection, dosing strategy, and study endpoints are aligned with the compound’s mechanism of action and clinical development strategy.

Therapeutic modalities

Biotrial supports the evaluation of a broad spectrum of oncology therapies reflecting the diversity of modern cancer treatments.

Chemotherapies
traditional cytotoxic agents used to inhibit tumor growth and proliferation.
Targeted therapies
small molecules or biologics designed to inhibit specific oncogenic pathways.
Immunotherapies
- Immune checkpoint inhibitors
- CAR-T cell therapies
- Antibody-drug conjugates (ADCs)

Radiotherapy approaches
including strategies combining radiation with systemic therapies.
Gene and nucleic acid therapies
- Adeno-associated viral vectors (AAV)
- Lipid nanoparticles (LNP)
- Antisense Oligonucleotides (ASO)
Combination treatment strategies
increasingly used in oncology to enhance therapeutic efficacy and overcome resistance mechanisms.

Oncology models

Biotrial offers a comprehensive portfolio of in vivo tumor models to evaluate anticancer therapies in physiologically relevant systems.

Syngeneic models
Xenograft models
Humanized mouse models
Ectopic and orthotopic implantation models

Oncology research capabilities

Surgery & model development

These techniques allow tumors to be implanted in anatomically relevant locations, improving the translational relevance of nonclinical models.

Ectopic & Orthotopic tumor implantations (Brain, lung, liver, Mammary Fat Pad, Ovary, etc.)

Discover oncotrial: A COLLABORATIVE APPROACH
TO INNOVATIVE ONCOLOGY MODEL DEVELOPMENT

Live imaging technologies

To monitor tumor progression and treatment response, we implement advanced non-invasive imaging techniques including:

Bioluminescence imaging
Fluorescence imaging
MRI imaging

These technologies enable real-time tumor monitoring, metastasis tracking, and longitudinal efficacy evaluation, allowing researchers to follow disease progression throughout the course of a study.

Biomarkers & Translational Endpoints

Biotrial integrates translational biomarkers into nonclinical study designs to strengthen the predictive value of experimental data.

We integrate biomarker analysis including:

Flow cytometry for immune cell profiling and tumor microenvironment characterization
Cytokine analysis to assess immune activation and inflammatory responses
Pharmacokinetic (PK) / Pharmacodynamic (PD) studies to correlate drug exposure with therapeutic efficacy
Genetic and molecular endpoints to evaluate pathway modulation and treatment mechanisms

This biomarker-driven strategy supports mechanism validation, translational relevance, and regulatory-ready data packages for IND submissions.